Germline variants in targeted tumor sequencing using matched normal DNA

JAMA Oncology

Volumn 2, Issue 1, 2016, Pages 104-111

  Schrader, Kasmintan A ^a,b,c   Cheng, Donavan T ^a   Joseph, Vijai ^a   Prasad, Meera ^a   Walsh, Michael ^a   Zehir, Ahmet ^a   Ni, Ai ^a   Thomas, Tinu ^a   Benayed, Ryma ^a   Ashraf, Asad ^a   Lincoln, Annie ^a   Arcila, Maria ^a   Stadler, Zsofia ^a   Solit, David ^a,d   Hyman, David M ^a   Zhang, Liying ^a   Klimstra, David ^a   Ladanyi, Marc ^a   Offit, Kenneth ^a,d   Berger, Michael ^a,d   Robson, Mark ^a,d   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADULT; AGED; BIOLOGICAL MODEL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; HUMAN; MALE; MIDDLE AGED; NEOPLASMS; NEW YORK; PATHOLOGY; PERSONALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; MODELS, GENETIC; NEOPLASMS; NEW YORK CITY; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84973444882     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.5208     Document Type: Conference Paper

References (28)

1. Hyman DM, Solit DB, Arcila ME, et al. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today. S1359-6446(15)00321-9 .
2. Bell CJ, Dinwiddie DL, Miller NA, et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med. 2011;3 (65):65ra4.
3. Tabor HK, Auer PL, Jamal SM, et al; NHLBI Exome Sequencing Project. Pathogenic variants for Mendelian and complex traits in exomes of 6,517 European and African Americans: implications for the return of incidental results. Am J Hum Genet. 2014;95(2):183-193.
4. Dorschner MO, Amendola LM, Turner EH, et al; National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project. Actionable, pathogenic incidental findings in 1,000 participants' exomes. Am J Hum Genet. 2013;93(4): 631-640.
5. Jones S, Anagnostou V, Lytle K, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med. 2015; 7(283):283ra53.
6. Kanchi KL, Johnson KJ, Lu C, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun. 2014;5:3156.
7. Stadler ZK, Schrader KA, Vijai J, Robson ME, Offit K. Cancer genomics and inherited risk. J Clin Oncol. 2014;32(7):687-698.
8. Green RC, Berg JS, Grody WW, et al; American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15(7):565-574.
9. Bombard Y, Robson M, Offit K. Revealing the incidentalome when targeting the tumor genome. JAMA. 2013;310(8):795-796.
10. Parsons DW, Roy A, Plon SE, Roychowdhury S, Chinnaiyan AM. Clinical tumor sequencing: an incidental casualty of the American College of Medical Genetics and Genomics recommendations for reporting of incidental findings. J Clin Oncol. 2014;32(21):2203-2205.
11. Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3): 251-264.
12. Babraham Bioinformatics. Taking appropriate QC measures for RRBS-type or other -Seq applications with Trim Galore! http://www.bioinformatics.babraham.ac.uk/projects/trim-galore/. Accessed October 1, 2013.
13. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. http://arxiv .org/abs/1303.3997. Accessed October 1, 2013.
14. McKenna A, Hanna M, Banks E, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9): 1297-1303.
15. Picard. http://broadinstitute.github.io/picard/. Accessed November 20, 2014.
16. Mose LE, Wilkerson MD, Hayes DN, Perou CM, Parker JS. ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics. 2014;30(19):2813-2815.
17. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213-219.
18. Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012;28(18):i333-i339.
19. NHLBI Exome Sequencing Project (ESP). Exome Variant Server. http://evs.gs.washington.edu /EVS/. Accessed June 15, 2014.
20. Richards S, Aziz N, Bale S, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424.
21. Wilson EB. Probable inference, the law of succession, and statistical inference. J AmStat Assoc. 1927;22(158):209-212.
22. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487.
23. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26): 2488-2498.
24. Kilpivaara O, Mukherjee S, Schram AM, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positivemyeloproliferative neoplasms. Nat Genet. 2009;41(4): 455-459.
25. Xie M, Lu C,Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12): 1472-1478.
26. Quadro L, Fattoruso O, Cosma MP, et al. Loss of heterozygosity at the RET protooncogene locus in a case of multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab. 2001;86(1):239-244.
27. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-2520.
28. Bombard Y, Offit K, Robson ME. Risks to relatives in genomic research: a duty to warn? Am J Bioeth. 2012;12(10):12-14.